Precision Medicine Trial Reports Preliminary Cognitive Improvement in Early Dementia Using Personalised Approach
核心洞察
The Evanthea Dementia (搜索) Reversal Trial announced preliminary results from a randomised controlled trial using a personalised precision medicine approach for mild cognitive impairment (搜索) and early dementia.
Lead investigator Dr. Kat Toups stated no other interventional trial has produced results of this magnitude for cognitive improvement and dementia (搜索) reversal in early disease.
The trial builds on the 2022 ReCODE proof-of-concept study, targeting individual biological drivers such as metabolic dysfunction, inflammation, and nutrient deficiencies rather than a single pathological pathway.
Preliminary results from the Evanthea Dementia (搜索) Reversal Trial, a randomised controlled study evaluating a personalised precision medicine approach in patients with mild cognitive impairment (搜索) (MCI) and early dementia, will be presented at the Integrative & Personalised Medicine Congress on June 19, 2026, in London. The findings, currently available as a preprint on PrePrints.org with over 14,800 downloads and submitted for peer review, represent what the lead investigator describes as a critical turning point in neurodegenerative disease treatment.
"To our knowledge, there is no other interventional trial producing results of this magnitude for cognitive improvement and dementia (搜索) reversal in early disease," said Kat Toups, MD, Principal Investigator of the trial and a geriatric neuropsychiatrist at Bay Area Wellness. "These preliminary findings represent a critical turning point in how we understand and treat neurodegenerative disease by addressing the underlying contributors and drivers of the disease."
A Growing Public Health Crisis
According to the Alzheimer's Society, approximately 982,000 people are living with dementia (搜索) in the UK, a figure projected to rise to 1.4 million by 2040. Dementia has been the leading cause of death in the UK for more than a decade. Globally, the condition affects more than 55 million people, with limited therapeutic options that significantly alter disease progression.
Trial Design and Methodology
The Evanthea trial was a pragmatic randomised multicenter controlled trial in which participants were randomised to either a 9-month precision medicine treatment approach or a 9-month standard treatment approach. The standard treatment group had the option to receive up to six months of precision medicine treatment and testing at no cost following trial completion. Both groups underwent cognitive assessments, MRI head scans, and blood testing at baseline, with tests repeated throughout the study alongside monthly physician appointments. Exploratory endpoints included assessments of blood pressure, weight, cholesterol, and additional markers for pre-diabetes.
Building on Prior Evidence
The trial builds on the Four Winds 2022 proof-of-concept Reversal of Cognitive Decline (ReCODE) Study, which was the first to demonstrate that cognitive decline can be modified when underlying contributors are systematically addressed. These contributors include metabolic dysfunction, inflammation, nutrient deficiencies, hormonal imbalance and deficiencies, infections, immune dysregulation, vascular factors, and toxin exposure.
"This study confirms earlier reports and pilot trials and offers real hope: mild cognitive impairment (搜索) and early dementia (搜索) are not irreversible," said Dale Bredesen, MD, Lead Study Advisor and Senior Director of the Precision Brain Health Program at Pacific Neuroscience Institute (搜索). "With the right assessments and a precision-guided treatment strategy, meaningful cognitive recovery is very often possible."
A New Treatment Framework
The EVANTHEA preliminary findings offer a framework that prioritises individual biology, early identification of causes, and personalised intervention rather than targeting a single pathological pathway. The trial was supported by the Four Winds Foundation (搜索) and performed by the Alzheimer's Prevention and Reversal Project (搜索) (APRP), an organisation dedicated to advancing precision medicine approaches to neurodegenerative disease.
Craig Tanio, MD, co-investigator and co-founder of Rezilir Health, added: "For patients, families, and clinicians alike, these preliminary results open the door to a future where cognitive decline is no longer accepted as inevitable."
The intervention evaluated in the Evanthea Trial is not approved by the U.S. Food and Drug Administration for the treatment, cure, or prevention of Alzheimer's disease (搜索), MCI, or dementia (搜索). The presentation by Dr. Toups, titled "Reversing Cognitive Decline: Groundbreaking Results from a Randomized Controlled Trial of Precision Medicine in Alzheimer's Disease," is scheduled for 15:05–15:45 on June 19 in the Mountbatten Room at the QEII Centre in London.